Background: M6620 is a novel inhibitor of the DNA damage repair enzyme ATR, and has potentiated the activity of cisplatin and irinotecan in non-small cell lung cancer and colon cancer xenografts, respectively. Conclusions: M6620 showed modest potentiation of cisplatin and melphalan activity for some cell lines. M6620 showed little single-agent activity and the addition of M6620 to cisplatin significantly prolonged time to event for a minority of tested xenografts across several histologies.
INTRODUCTION
Agents that damage DNA such as cyclophosphamide, cisplatin, topoisomerase poisons, and ionizing radiation remain the backbone of curative therapy for many childhood cancers. The cytotoxic effect of these agents is best correlated with induction of DNA strand breaks, particularly double strand breaks that trigger the cascade of events leading to apoptosis. The effectiveness of these agents is limited by repair of The DNA damage response (DDR) is regulated by two homologous protein kinases, ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3 related (ATR). ATM-CHK2 and ATR-CHK1 (where CHK2 and CHK1 are checkpoint kinase 2 and checkpoint kinase 1, respectively) checkpoints are central genome surveillance systems that function to maximize cell survival while minimizing genome instability. 1 Activated CHK2 and CHK1 phosphorylate downstream effectors to amplify and relay the signals to engage DDR leading to cell cycle arrest, DNA damage repair, senescence, or apoptosis. 2, 3 The major functions of checkpoints are to facilitate DNA repair and promote recovery from replication stalling, [4] [5] [6] thereby maintaining cell survival. DNA replication forks undergo frequent stalling during normal cell cycle progression when they encounter endogenous DNA lesions estimated to occur at a frequency of at least 2 × 10 4 per cell/day. 7 Stabilization of stalled replication forks is regulated by a highly conserved process involving ATR-CHK1, which makes the ATR-CHK1 checkpoint essential for cell survival in all eukaryotes. 2 Eukaryotes have a highly efficient DNA repair network where, under normal growth conditions, the baseline DNA damage incurred from extracellular and intracellular agents is rapidly repaired and there is no checkpoint activation. However, in response to massive DNA damage, DNA damage checkpoints will be activated to arrest cell cycle progression in order to provide time for repair machinery to repair DNA lesions.
Thus, through checkpoint signaling genome integrity is maintained, 3, 8, 9 and defects in DDR facilitate emergence of genetically unstable cancer cells.
It has long been recognized that AT patients are hypersensitive to ionizing radiation, and defects in DDR predispose to cells becoming hypersensitive to DNA-damaging agents. Emerging clinical data show that ovarian cancers deficient in homologous recombination as a consequence of breast cancer type 1/2 susceptibility protein (BRCA 1/2) mutations respond better to cisplatin-based therapy than do cancers with wild-type BRCA genes. [10] [11] [12] Similarly, responses to platinum-based therapy are reported to be better in patients with lung cancers with mutated or compromised excision repair crosscomplementing rodent repair deficiency, complementation group 1 (ERCC1) function 13 raising the anticipation that many defects in DDR may predispose cancer cells to cytotoxic effects of chemotherapy.
Indeed, hypersensitivity to the poly-ADP ribose polymerase inhibitor talazoparib (and to cisplatin) in a Wilms tumor xenograft model was associated with a mutation in partner and localizer of BRCA2 (PALB2), a protein that plays a critical role in homologous recombination repair through its ability to recruit BRCA2 and radiation-sensitive gene 51 (RAD51) to DNA breaks. 14 It has been proposed that a combination of replication stress and defective ATM signaling (as a consequence of defects upstream such as loss of p53 function) may promote reliance on ATR signaling to maintain cell viability. [15] [16] [17] Thus, it has been proposed that ATR inhibition may increase the effectiveness of DNA-damaging chemotherapeutics such as cisplatin, 18 topoisomerase I poisons, 19 and ionizing radiation. 20 M6620 is a potent and selective inhibitor of ATR that has entered clinical trials and is being studied as a single agent and in combination with radiation therapy and with agents that induce DNA damage (e.g., cisplatin/carboplatin, gemcitabine, irinotecan). 18, 20, 21 In this report, we present evaluation of M6620 as a single agent, or in combination with cisplatin or melphalan in pediatric cancer cell lines and in combination with cisplatin in xenograft models derived from pediatric cancers.
MATERIALS AND METHODS

In vitro testing
Testing was performed using DIMSCAN, a semiautomatic fluorescence-based digital image microscopy system that quantifies viable (using fluorescein diacetate) cell numbers in tissue culture multiwell plates using standard Pediatric Preclinical Testing Program (PPTP) procedures described previously. 22 Combination testing was performed using methods previously applied to testing cytotoxic agents with rapamycin. 23 Data obtained for the cytotoxic alone were normalized to controls with no M6620 present and data obtained for the combination were normalized to controls with 75 nM M6620 present. Using these normalized data, rIC 50 values were determined for the agent in the presence and absence of M6620, and the ratio of the two values was used to evaluate for potentiation induced by M6620. Cisplatin was tested at concentrations from 3 nM to 10 M, and melphalan was tested at concentrations from 10 nM to 30 M.
In vivo testing
CB17SC scid −/− female mice (Taconic Farms, Germantown NY) were used to propagate subcutaneously implanted kidney/rhabdoid tumors, sarcomas (Ewing, osteosarcoma, rhabdomyosarcoma), neuroblastoma, and brain tumors. Female mice were used irrespective of the patient gender from which the original tumor was derived. All mice were maintained under barrier conditions and experiments were conducted using protocols and conditions approved by the institutional animal care and use committee at the Research Institute, Nationwide Children's Hospital. Ten mice were used in each control or treatment group.
Tumor volumes (cm 3 ) and responses were determined using three activity measures as previously described. 24 An in-depth description of the analysis methods is included in the Supplementary Response Definitions S1 section. 
Statistical methods
The exact log-rank test, as implemented using Proc StatXact for SAS R , was used to compare event-free survival (EFS) distributions between treatment and control groups. P-values were two-sided and were not adjusted for multiple comparisons given the exploratory nature of the studies. P-values equal to or <0.05 were considered statistically significant. Objective response is defined as ≥50% tumor volume regression in treated animals. The Pearson correlation coefficient was used to explore the relationship between potentiation of cisplatin and melphalan by M6620 across the cell lines.
Drugs and formulation
M6620 was provided to the PPTP by Vertex Pharmaceuticals (Europe)
Inc. through the Cancer Therapy Evaluation Program (NCI). M6620
was formulated as a 20 mg/ml suspension in 5% captisol/3% manni- The relative I/O% values compare the relative difference in final cell number compared to the starting cell number for treated cells and for control cells. Relative I/O% values range between 100% (no treatment effect) and −100% (complete cytotoxic effect), with a relative I/O% value of 0% being observed for a completely effective cytostatic agent.
RESULTS
M6620 in vitro testing
As shown in Table 1 , all PPTP cell lines showed a pronounced cytotoxic effect at the higher concentrations tested, with relative I/O% values approaching −100% for all cell lines.
M6620 in vitro combination testing
To test for the ability of M6620 to potentiate the cytotoxic activity of standard chemotherapy agents, it was tested at a fixed concentra- Table S1 ).
M6620 in vivo testing
M6620 as a single agent induced significant differences in EFS distribution compared to control in 5 of 24 (21%) of the solid tumor xenografts studied (Table 3) Specific comparisons were made between the EFS distributions of the M6620 plus cisplatin combination and single-agent cisplatin and single-agent M6620, respectively (Table 4) . Of special interest were models for which the combination was significantly superior to singleagent cisplatin (P < 0.05). Four of 24 models met this criterion, including BT-29 (rhabdoid tumor), KT-5 (Wilms tumor), NB-EBc1 (neuroblastoma), and OS-9 (osteosarcoma). Examples of tumor volume growth curves and Kaplan-Meier EFS for these solid tumor xenografts for which the EFS distribution for the M6620 plus cisplatin combination significantly exceeded that for single-agent cisplatin are shown in Figure 2 . The most substantial potentiation of activity was observed for KT-5, for which the addition of M6620 led to complete responses in many animals that were maintained for 4 or more weeks. The potentiation observed for BT-29 and NB-EBc1, although significant, was more modest.
As ATM deficiency has been reported to predict for sensitivity to ATR inhibitors, the mutation status of ATM was examined. Exome sequencing identified predicted deleterious mutations in ATM in only the glioblastoma line GBM2 (p.G494C in exon 10) and the ALL cell line MOLT-4 (p.S2165F in exon 45) (sequencing data deposited at NCI TARGET Data Matrix). MOLT-4 showed a relatively low rIC 50 and was the cell line that showed the greatest potentiation of cisplatin activity by M6620. The rIC 50 for GBM2 was at the median for the entire panel, and M6620 did not potentiate either cisplatin or melphalan activity for this cell line. M6620 did not significantly increase toxicity of cisplatin, and the M6620-cisplatin combination induced significant differences in EFS distribution compared to control in the vast majority of lines tested (88%), with four objective responses. However, there were only four models for which the antitumor response to cisplatin was significantly enhanced in combination with M6620. The greatest effect was observed for KT-5 Wilms tumor for which the combination induced CR with a marked increase in time to event compared to cisplatin (P < 0.0001). Other statistically significant differences between cisplatin and the combination were observed for BT-29 CNS rhabdoid tumor, NB-EBc1 neuroblastoma, and OS-9 osteosarcoma models (Supplementary Table S1 ). For BT-29 the response was changed from PD1
to PD2, whereas addition of M6620 to cisplatin did not change the overall group response for the other models, the time to event was extended over that for cisplatin alone treatment. Hall et al. reported more consistent in vivo potentiation of cisplatin by M6620 using nonsmall cell lung cancer (NSCLC) xenograft lines than that observed for the PPTP pediatric xenograft lines. 18 Potential reasons include differences in the biology of NSCLC lines compared to our pediatric Results of phase 1 trials of M6620 as a single agent and in combination with either cisplatin or carboplatin have been reported.
As a single agent, IV doses of up to 480 mg/m 2 administered weekly were tolerated without dose-limiting toxicities observed. 25 In combination with carboplatin (AUC 5) administered on day 1, recommended phase 2 dose of M6620 is 90 mg/m 2 administered intravenously on days 2 and 9. 25 Dose-limiting toxicities at higher M6620 doses were primarily hematologic and included febrile neutropenia as well as carboplatin dose delays due to neutropenia and/or thrombocytopenia. The phase 1 evaluation of cisplatin and M6620
used the same administration schedule as that studied for carboplatin, and the recommended phase 2 doses are 75 mg/m 2 for cisplatin and 140 mg/m 2 for M6620. 26 The maximum tolerated combination dose was not reached because dose escalation was stopped as M6620 systemic exposure at 140 mg/m 2 exceeded drug levels shown in preclinical models to produce target engagement and tumor regression in combination with cisplatin. 26 Objective responses were observed in 4 patients (among 28 patients enrolled), including 3 patients with platinum-resistant/refractory tumors.
ATM deficiency has been reported to predict for sensitivity to ATR inhibitors in preclinical testing. 15, 17 As well, a patient with colorectal cancer whose tumor was ATM negative by immunohistochemical testing showed a complete response to single-agent M6620. 25 In summary, M6620 showed modest potentiation of cisplatin and melphalan activity for some PPTP cell lines. M6620 showed little single-agent activity against pediatric solid tumor xenografts. The addition of M6620 to cisplatin significantly prolonged time to event for a minority of tested xenografts across several histologies.
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